Status:
COMPLETED
Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium
Lead Sponsor:
AstraZeneca
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18+ years
Brief Summary
This is a retrospective, observational, multicentre study to evaluate treatment patterns and outcomes of patients diagnosed with locally advanced or metastatic EGFRm NSCLC in Belgium
Eligibility Criteria
Inclusion
- Male or female, aged at least 18 years
- Pathologically confirmed NSCLC
- Tumour harbours a mutation of EGFR
- Diagnosis (radiologically or pathologically confirmed) of locally advanced or metastatic NSCLC, not amenable to curative surgery or chemoradiotherapy between 01 September 2015 and 31 December 2017
Exclusion
- No follow-up data available after diagnosis of locally advanced or metastatic EGFRm NSCLC
- Patients who objected to participation to the study
Key Trial Info
Start Date :
September 21 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 19 2019
Estimated Enrollment :
141 Patients enrolled
Trial Details
Trial ID
NCT03761901
Start Date
September 21 2018
End Date
June 19 2019
Last Update
May 8 2020
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Antwerp, Belgium, 2020
2
Research Site
Bouge, Belgium, 5004
3
Research Site
Brussels, Belgium, 1090
4
Research Site
Brussels, Belgium, 1200